GoldenGolden
Arcturus Therapeutics

Arcturus Therapeutics

Arcturus Therapeutics is a lipid nanoparticle (LNP) siRNA drug delivery systems founded in 2013 by Joseph Payne.

Specializing in RNA medicines, Arcturus Therapeutics focuses on diseases with high unmet needs.

Technologies

Their central product is a proprietary technology known as "LUNAR"(Lipid-enabled and Unlocked

Nucleomonomer Agent modified RNA). "LUNAR" is a delivery system that consists of a combination of RNAs and gene editing tools.

LUNAR-COV19

Arcturus in collaboration with Duke-National University of Singapore is developing an RNA based prophylactic vaccine to prevent COVID19 coronavirus infection.

The LUNAR-COVID19 combines Arcturus' self-replicating RNA STARR™ Technology with their LUNAR® RNA medicine delivery technology to develop a prophylactic vaccine against SARS-CoV-19. The combination of these two technologies results in (1) a RNA vaccine that can be produced more rapidly than conventional adjuvanted protein based vaccines, (2) a dramatic reduction in the RNA dose required to elicit a protective immune response, and (3) an increase in the duration of antigen expression potentially yielding protective immunity from SARS-CoV-19 with a single dose.

Timeline

October 21, 2013
Arcturus Therapeutics raises a $5,000,000 series A round.
June 7, 2013
Arcturus Therapeutics raises a $1,300,000 seed round.
April 2013
Arcturus Therapeutics raises a $580,000 seed round.
2013
Arcturus Therapeutics was founded by Joseph Payne and Pad (Padmanabh) Chivukula.

Funding rounds

People

Name
Role
LinkedIn

Andrew Sassine

Chief Financial Officer

Dr. Steve Hughes

Chief Development Officer

Joseph E. Payne

President & CEO

Padmanabh Chivukula

CSO & COO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Emily Graffeo
December 29, 2020
markets.businessinsider.com
The Singapore Health Sciences Authority approved the Arcturus vaccine candidate for Phase 2 clinical studies, though Wall Street was disappointed the medical company's latest vaccine update.
November 9, 2020
BioSpace
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore - read this article along with other careers information, tips and advice on BioSpace
Martin Farrer
August 21, 2020
the Guardian
Travellers wear protective gear agianst the threat of coronavirus as they arrive in Los Angeles from New York. Photograph: Ringo Chiu/ZUMA Wire/REX/Shutterstock
BioSpace
June 5, 2020
BioSpace
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company's messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.